By following this link you will be leaving a Takeda controlled website for a third party website
Please note that Takeda is not responsible or liable for any third party website and the website may not be appropriate for all audiences.
For adults with Chronic Idiopathic Constipation (CIC)
The checklist below may help determine whether your patients may be looking for something that works differently.
Patient ID Tool
With your patient with CIC in mind, going through this checklist may help you uncover if they are looking for a different treatment approach.
Want to save a copy of this checklist to use later? Click here to download the PDF.
Have your patients...
Expressed frustration with recurring symptoms?
Had less than 3 complete
movements per week?
Felt a sense of
Stopped taking their
CIC medication as prescribed?
Colonic dysmotility could be a factor affecting your patients with CIC.1
Consider a prokinetic approach for patients looking for a treatment that works differently.
Interested in learning about the
Mechanism of Action for Motegrity?
Not a real patient
Please expand for Indication and Important Safety Information.
Warnings and Precautions
Suicidal Ideation and Behavior: In clinical trials, suicides, suicide attempts and suicidal ideation have been reported. Postmarketing cases of suicidal ideation and behavior as well as self-injurious ideation and new onset or worsening of depression have been reported within the first few weeks of starting Motegrity. A causal association between treatment with Motegrity and an increased risk of suicidal ideation and behavior has not been established. Monitor patients for new onset or worsening of depression and emergence of suicidal thoughts and behavior. Instruct patients to discontinue Motegrity immediately and contact their healthcare provider if they experience any of these symptoms.
Most common adverse reactions (≥2%) are headache, abdominal pain, nausea, diarrhea, abdominal distension, dizziness, vomiting, flatulence, and fatigue.
Use in Specific Populations
Motegrity® (prucalopride) is a serotonin-4 (5-HT4) receptor agonist indicated for the treatment of chronic idiopathic constipation (CIC) in adults.
Please click here for full Prescribing Information.
Reference: 1. Dinning PG, Di Lorenzo C. Best Pract Res Clin Gastroenterol. 2011;25(1):89-101.